Fat Science

Taking a GLP-1 medication when your body does not need it can actually harm your health. Dr. Emily Cooper breaks down who these drugs are truly for.
Dr. Emily Cooper, Mark Wright, and Andrea Taylor tackle the cultural assumption that everyone needs to be on a GLP-1 medication. They examine how marketing and social media trends have pushed these clinical tools into the realm of casual quick fixes, overlooking the biology of how they actually function inside the body.
The discussion centers on the medical reality that a high body weight alone does not automatically mean a person is metabolically unhealthy. Dr. Cooper explains the expanded health indications for these medications, why severe calorie restriction while taking them causes lean mass loss, and what objective health markers actually justify pharmacologic treatment.
Fat Science, Dr. Cooper, and the Diabesity Institute have no financial relationship with any pharmaceutical company. This conversation focuses on separating individualized metabolic care from commercial pressure, exploring alternative treatments like metformin, and understanding why a lack of response to these drugs is never the patient's fault.
Key Takeaways
GLP-1 medications are designed for specific metabolic dysfunctions, not for casual use or minor weight changes.

A higher body weight does not automatically indicate poor metabolic health, and up to 25% of individuals with normal weight have underlying metabolic comorbidities.

Severe calorie restriction on a GLP-1 leads to significant loss of lean muscle mass rather than healthy metabolic stabilization.

Alternative medications like metformin, Contrave, or SGLT2 inhibitors may target individual root issues more effectively than GLP-1s alone.

If a medication does not produce results, it reflects the limitations of current medical therapies rather than personal failure.

Resources Mentioned
Cooper Center for Metabolism
Diabesity Institute
Connect with Us
Podcast Home:fatsciencepodcast.com
Cooper Center for Metabolism:coopermetabolic.com
Diabesity Institute: diabesityinstitute.org
Resources from Dr. Cooper:coopermetabolic.com/resources
Join Our Community:patreon.com/cw/FatSciencePodcast
Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com
Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.
This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
Produced by: Podcast Impact Studio https://podcastimpactstudio.com

When your body holds onto weight or reacts to exercise with fatigue and headaches, restriction is rarely the fix. Fueling consistently comes first.
Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener questions from around the world. The conversation addresses standard metabolic screenings, the risks of using weight loss medications during active eating disorders, and why disproportionate lower body fat may point to conditions like lipedema.
The team also examines HbA1c test variability, adult-onset autoimmune diabetes genetics, and why severe restriction causes the brain to raise metabolic defenses. Finally, Dr. Cooper breaks down how intense exercise acts as a physiological stressor and why adequate recovery matters more than pushing through burnout.
Key Takeaways
Fasting insulin is often excluded from routine panels despite providing early insight into cardiovascular and metabolic risk.

Active eating disorders disrupt metabolic hormones and require specialized treatment before metabolic health can be evaluated.

Disproportionate lower extremity fat storage that resists lifestyle interventions may signal lipedema rather than standard adipose tissue.

HbA1c tests can fluctuate by up to 0.2 points, making long-term patterns and mixed meal tolerance tests far more informative.

Exercise elevates stress hormones, and working out while sleep-deprived or under-fueled breaks the body down instead of strengthening it.

Resources Mentioned
Diabesity Foundations Course
Mechanical Eating Guide on Patreon
Connect with Us
Podcast Home:fatsciencepodcast.com
Cooper Center for Metabolism:coopermetabolic.com
Diabesity Institute: diabesityinstitute.org
Resources from Dr. Cooper:coopermetabolic.com/resources
Join Our Community:patreon.com/cw/FatSciencePodcast
Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com
Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.
This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
Produced by: Podcast Impact Studio https://podcastimpactstudio.com

Metabolic medications work by mimicking natural gut hormones and brain signals, not just by slowing down the digestive tract.
Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down the rapidly evolving landscape of metabolic therapies. From oral options to high-dose formulations and pipeline molecules, the conversation cuts through public confusion to focus on biological mechanisms.
The discussion explores how these therapies interact with complex melanocortin and hormonal pathways in the brain. Rather than relying on rigid protocols or escalating doses prematurely, effective metabolic care focuses on individual biological response and measurable health parameters.
Key Takeaways
Modern metabolic therapies are designed to mimic native hormones like GLP-1, GIP, and amylin rather than simply slowing gastric emptying.

Clinical trial dosing sequences are designed for regulatory approval, while individualized clinical practice prioritizes symptom stability and health markers over reaching maximum doses.

Health improvements such as blood pressure regulation, cholesterol shifts, and liver markers often occur independently of scale changes.

Resources Mentioned
Diabesity Institute Foundations Course
Cooper Center for Metabolism
Connect with Us
Podcast Home:fatsciencepodcast.com
Cooper Center for Metabolism:coopermetabolic.com
Diabesity Institute: diabesityinstitute.org
Resources from Dr. Cooper:coopermetabolic.com/resources
Join Our Community:patreon.com/cw/FatSciencePodcast
Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com
Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.
This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
Produced by: Podcast Impact Studio https://podcastimpactstudio.com

Wondering why weight stalls on treatment? Dr. Emily Cooper explains how the brain defends set points and why eating less stops progress.
Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener letters from around the world. The conversation addresses why athletic men with a BMI of 27 can still show high visceral fat on a DEXA scan, how medications defend metabolic set points, and why intentional undereating triggers starvation responses.
The team also examines global access to metabolic treatments, dual incretin agonists versus single agonists, artificial sweeteners, and how to interpret two-hour insulin and glucose tolerance curves.
Key Takeaways
Rapid weight reduction without adequate nutrition can cause lean mass loss and trigger metabolic defense mechanisms.
Dual incretin therapies stimulate GIP receptors far more than GLP-1 receptors compared to natural human hormones, creating different patient responses.
Intentional calorie restriction reduces natural incretin production and can impair metabolic signaling, making mechanical fueling essential.
Fasting insulin suppression combined with pre-diabetes indicators can reflect the brain pulling glucose during periods of low carbohydrate intake.
Resources Mentioned
Diabesity Foundations Course
Cooper Center for Metabolism
Diabesity Institute
Connect with Us
Podcast Home:fatsciencepodcast.com
Cooper Center for Metabolism:coopermetabolic.com
Diabesity Institute: diabesityinstitute.org
Resources from Dr. Cooper:coopermetabolic.com/resources
Join Our Community:patreon.com/cw/FatSciencePodcast
Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com
Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.
This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
Produced by: Podcast Impact Studio https://podcastimpactstudio.com

What do new drug reports really mean for your treatment?
Explore groundbreaking updates on potential diabetes and weight-loss drugs from Novo Nordisk and Eli Lilly. Dr. Emily Cooper dives into top-line results, explaining what these findings mean for those struggling with metabolic issues.
KEY TAKEAWAYS
Understanding the difference between efficacy estimand and treatment policy estimand.

Cagrisema’s potential in aiding weight loss compared to Mounjaro in patients with type 2 diabetes.

Semaglutide's effectiveness in children and its implications.

NOTABLE QUOTE
"Many of our patients with metabolic dysfunction have increased cardiometabolic risk." — Dr. Emily Cooper
LINKS & RESOURCES
Learn more about Diabesity Foundations: learn.diabesityinstitute.org
Podcast Home: fatsciencepodcast.com
Cooper Center for Metabolism: coopermetabolic.com
Diabesity Institute: diabesityinstitute.org
Resources from Dr. Cooper: coopermetabolic.com/resources
Join Our Community: patreon.com/cw/FatSciencePodcast
Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com
Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.
This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.